Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues Authors: David L. Rimm [email protected], ...
With respect to assay development, quality assurance and, ultimately, clinical adoption, the primary subject of this review, these advantages are critical. Implicit with these advantages, TMAs enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback